149 related articles for article (PubMed ID: 20890374)
21. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer.
Cheng F; McLaughlin PJ; Verderame MF; Zagon IS
Mol Cancer; 2008 Jan; 7():5. PubMed ID: 18190706
[TBL] [Abstract][Full Text] [Related]
22. Opioid growth factor - opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer.
Zagon IS; Porterfield NK; McLaughlin PJ
Exp Biol Med (Maywood); 2013 Jun; 238(6):589-99. PubMed ID: 23918871
[TBL] [Abstract][Full Text] [Related]
23. Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture.
Zagon IS; Hytrek SD; McLaughlin PJ
Am J Physiol; 1996 Sep; 271(3 Pt 2):R511-8. PubMed ID: 8853370
[TBL] [Abstract][Full Text] [Related]
24. Elevated serum [Met
Ludwig MD; Zagon IS; McLaughlin PJ
Brain Res Bull; 2017 Sep; 134():1-9. PubMed ID: 28647454
[TBL] [Abstract][Full Text] [Related]
25. Identification and characterization of opioid growth factor receptor in human pancreatic adenocarcinoma.
Zagon IS; Smith JP; Conter R; McLaughlin PJ
Int J Mol Med; 2000 Jan; 5(1):77-84. PubMed ID: 10601579
[TBL] [Abstract][Full Text] [Related]
26. [Possibilities of palliation in pancreatic cancer].
Di Costanzo F; Sdrobolini A; Gasperoni S
Tumori; 1999; 85(1 Suppl 1):S47-53. PubMed ID: 10235081
[TBL] [Abstract][Full Text] [Related]
27. Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice.
McLaughlin PJ; Levin RJ; Zagon IS
Cancer Lett; 2003 Sep; 199(2):209-17. PubMed ID: 12969794
[TBL] [Abstract][Full Text] [Related]
28. Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck.
McLaughlin PJ; Stucki JK; Zagon IS
Head Neck; 2012 Apr; 34(4):513-9. PubMed ID: 21584896
[TBL] [Abstract][Full Text] [Related]
29. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
Zagon IS; Donahue R; McLaughlin PJ
Exp Biol Med (Maywood); 2013 May; 238(5):579-87. PubMed ID: 23856908
[TBL] [Abstract][Full Text] [Related]
30. Regulation of Tenon's capsule fibroblast cell proliferation by the opioid growth factor and the opioid growth factor receptor axis.
Klocek MS; Sassani JW; Donahue RN; McLaughlin PJ; Zagon IS
Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):5054-61. PubMed ID: 20463323
[TBL] [Abstract][Full Text] [Related]
31. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells.
Zagon IS; Verderame MF; Hankins J; McLaughlin PJ
Int J Oncol; 2007 Apr; 30(4):775-83. PubMed ID: 17332915
[TBL] [Abstract][Full Text] [Related]
33. Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis.
Zagon IS; Rahn KA; Bonneau RH; Turel AP; McLaughlin PJ
Brain Res; 2010 Jan; 1310():154-61. PubMed ID: 19931226
[TBL] [Abstract][Full Text] [Related]
34. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.
Donahue RN; McLaughlin PJ; Zagon IS
Am J Physiol Regul Integr Comp Physiol; 2009 Jun; 296(6):R1716-25. PubMed ID: 19297547
[TBL] [Abstract][Full Text] [Related]
35. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.
Donahue RN; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2011 Jul; 236(7):883-95. PubMed ID: 21685240
[TBL] [Abstract][Full Text] [Related]
36. Weekly Gemcitabine plus Fluorouracil-Folinic Acid Given Weekly for Two Days in Patients with Advanced Pancreatic Cancer : A Phase II Study.
Polyzos A; Tsavaris N; Kosmas C; Gogas H; Koutinos G; Nikiteas NI; Felekouras E; Kouraklis G; Papadopoulos O; Papachristodoulou A; Stamatiadis D; Safioleas M; Nikou G
Clin Drug Investig; 2004; 24(11):661-70. PubMed ID: 17523729
[TBL] [Abstract][Full Text] [Related]
37. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer.
Cheng F; Zagon IS; Verderame MF; McLaughlin PJ
Cancer Res; 2007 Nov; 67(21):10511-8. PubMed ID: 17974995
[TBL] [Abstract][Full Text] [Related]
38. Opioid growth factor inhibits intimal hyperplasia in balloon-injured rat carotid artery.
Zagon IS; Essis FM; Verderame MF; Healy DA; Atnip RG; McLaughlin PJ
J Vasc Surg; 2003 Mar; 37(3):636-43. PubMed ID: 12618704
[TBL] [Abstract][Full Text] [Related]
39. Internalization of the opioid growth factor, [Met5]-enkephalin, is dependent on clathrin-mediated endocytosis for downregulation of cell proliferation.
Cheng F; McLaughlin PJ; Banks WA; Zagon IS
Am J Physiol Regul Integr Comp Physiol; 2010 Sep; 299(3):R774-85. PubMed ID: 20592180
[TBL] [Abstract][Full Text] [Related]
40. Opioid growth factor inhibition of a human squamous cell carcinoma of the head and neck in nude mice: dependency on the route of administration.
McLaughlin PJ; Stack BC; Braine KM; Ruda JD; Zagon IS
Int J Oncol; 2004 Jan; 24(1):227-32. PubMed ID: 14654962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
